AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

CYCC â€� Insider Transaction Summary (Form 4, filed 8/4/25)

  • Reporting person: David E. Lazar, previously a â‰�10% owner.
  • Transaction: On 07/30/25 Lazar sold 6,750 common shares at $12.36, an aggregate value of roughly $83.4k.
  • Post-sale stake: 155,838 common shares held directly.
  • Reverse split impact: Holdings reflect the 1-for-15 reverse split effected 07/07/25.
  • Exit filing: After this sale Lazar’s ownership fell below the 10% threshold, ending Section 16 insider status.
  • Prior error corrected: A February 28 filing mistakenly listed 354,738 Series D preferred shares that had already converted into 162,588 common shares (post-split).

Investor take-away: The divestiture is modest in absolute terms but material because it removes a former large shareholder from insider reporting requirements, potentially reducing future visibility into his trades. No derivative transactions or option activity were reported.

CYCC � Riepilogo Transazione Insider (Modulo 4, presentato il 4/8/25)

  • Persona che segnala: David E. Lazar, precedentemente proprietario di almeno il 10%.
  • Transazione: Il 30/07/25 Lazar ha venduto 6.750 azioni ordinarie a $12,36 ciascuna, per un valore complessivo di circa $83.400.
  • Quota dopo la vendita: 155.838 azioni ordinarie detenute direttamente.
  • Effetto del frazionamento inverso: Le partecipazioni riflettono il frazionamento inverso 1-per-15 effettuato il 07/07/25.
  • Segnalazione di uscita: Dopo questa vendita, la quota di Lazar è scesa sotto la soglia del 10%, terminando lo status di insider ai sensi della Sezione 16.
  • Correzione di errore precedente: Una segnalazione del 28 febbraio aveva erroneamente indicato 354.738 azioni privilegiate Serie D già convertite in 162.588 azioni ordinarie (post-frazionamento).

Considerazioni per l'investitore: La cessione è modesta in termini assoluti ma rilevante perché elimina un ex grande azionista dagli obblighi di segnalazione insider, riducendo potenzialmente la trasparenza sulle sue future operazioni. Non sono state segnalate transazioni derivati o attività su opzioni.

CYCC � Resumen de Transacción de Insider (Formulario 4, presentado el 4/8/25)

  • Persona que reporta: David E. Lazar, anteriormente propietario de â‰�10%.
  • °Õ°ù²¹²Ô²õ²¹³¦³¦¾±Ã³²Ô: El 30/07/25 Lazar vendió 6,750 acciones ordinarias a $12.36 cada una, por un valor total aproximado de $83,400.
  • Participación tras la venta: 155,838 acciones ordinarias en propiedad directa.
  • Impacto del split inverso: Las participaciones reflejan el split inverso 1 por 15 realizado el 07/07/25.
  • Presentación de salida: Tras esta venta, la propiedad de Lazar bajó del umbral del 10%, finalizando su condición de insider bajo la Sección 16.
  • Corrección de error previo: Una presentación del 28 de febrero listó erróneamente 354,738 acciones preferentes Serie D que ya se habían convertido en 162,588 acciones ordinarias (post-split).

Conclusión para el inversor: La desinversión es modesta en términos absolutos pero significativa porque elimina a un antiguo gran accionista de las obligaciones de reporte como insider, lo que podría reducir la visibilidad futura de sus operaciones. No se reportaron transacciones con derivados ni actividad en opciones.

CYCC â€� ë‚´ë¶€ìž� 거래 요약 (ì–‘ì‹ 4, 25ë…� 8ì›� 4ì� 제출)

  • ë³´ê³ ìž�: David E. Lazar, ì´ì „ì—� 10% ì´ìƒ 보유ìž�.
  • 거래 ë‚´ìš©: 25ë…� 7ì›� 30ì�, Lazarê°€ 6,750ì£� 보통주를 주당 $12.36ì—� 매ë„하여 ì´� ì•� $83,400ì� 가치를 기ë¡í•�.
  • ë§¤ë„ í›� 보유 ì§€ë¶�: ì§ì ‘ 보유í•� 155,838ì£� 보통ì£�.
  • 역병í•� ì˜í–¥: 25ë…� 7ì›� 7ì� 시행ë� 1대 15 ì—­ë³‘í•©ì„ ë°˜ì˜í•� 보유 지분임.
  • 퇴출 ì‹ ê³ : ì´ë²ˆ 매ë„ë¡� Lazarì� 보유 ì§€ë¶„ì´ 10% 미만으로 떨어ì � 섹션 16 ë‚´ë¶€ìž� 지위가 종료ë�.
  • ì´ì „ 오류 수정: 2ì›� 28ì� 제출ë� ë³´ê³ ì„œì— ì´ë¯¸ 162,588ì£� 보통ì£�(병합 í›�)ë¡� 전환ë� 354,738ì£� 시리ì¦� D 우선주가 잘못 기재ë˜ì—ˆì�.

투ìžìž� 참고 사항: ë§¤ë„ ê·œëª¨ëŠ� 절대ì ìœ¼ë¡œëŠ” í¬ì§€ 않지ë§�, ì´ì „ 대주주가 ë‚´ë¶€ìž� ë³´ê³  ì˜ë¬´ì—서 제외ë˜ì–´ 향후 거래 íˆ¬ëª…ì„±ì´ ê°ì†Œí•� ìˆ� 있으므ë¡� 중요í•�. 파ìƒìƒí’ˆ 거래ë‚� 옵션 활ë™ì€ ë³´ê³ ë˜ì§€ 않ìŒ.

CYCC � Résumé de la Transaction d’Initié (Formulaire 4, déposé le 4/8/25)

  • Personne déclarant : David E. Lazar, auparavant détenteur d’au moins 10%.
  • Transaction : Le 30/07/25, Lazar a vendu 6 750 actions ordinaires à 12,36 $ chacune, pour une valeur totale d’environ 83 400 $.
  • Participation après la vente : 155 838 actions ordinaires détenues directement.
  • Impact du regroupement inversé : Les avoirs tiennent compte du regroupement inversé de 1 pour 15 effectué le 07/07/25.
  • Dépôt de sortie : Après cette vente, la participation de Lazar est passée en dessous du seuil de 10%, mettant fin à son statut d’initié selon la Section 16.
  • Correction d’une erreur antérieure : Un dépôt du 28 février avait listé par erreur 354 738 actions privilégiées Série D déjà converties en 162 588 actions ordinaires (post-regroupement).

À retenir pour l’investisseur : La cession est modeste en valeur absolue mais importante car elle retire un ancien grand actionnaire des obligations de déclaration d’initié, ce qui pourrait réduire la visibilité future de ses transactions. Aucune opération sur dérivés ni activité d’options n’a été signalée.

CYCC � Zusammenfassung der Insider-Transaktion (Formular 4, eingereicht am 4.8.25)

  • Meldende Person: David E. Lazar, zuvor Eigentümer von â‰�10%.
  • Transaktion: Am 30.07.25 verkaufte Lazar 6.750 Stammaktien zu je $12,36, mit einem Gesamtwert von ca. $83.400.
  • Anteil nach Verkauf: 155.838 direkt gehaltene Stammaktien.
  • Auswirkung des Reverse Splits: Die Bestände spiegeln den 1-zu-15 Reverse Split wider, der am 07.07.25 durchgeführt wurde.
  • Austrittsmeldung: Nach diesem Verkauf fiel Lazars Anteil unter die 10%-Schwelle, womit der Insider-Status nach Abschnitt 16 endet.
  • Vorheriger Fehler korrigiert: Eine Meldung vom 28. Februar listete fälschlicherweise 354.738 Series-D-Vorzugsaktien, die bereits in 162.588 Stammaktien (nach dem Split) umgewandelt wurden.

Investorenausblick: Die Veräußerung ist absolut gesehen eher gering, aber bedeutsam, da ein ehemaliger Großaktionär von den Insider-Meldepflichten entbunden wird, was die künftige Transparenz seiner Transaktionen verringern könnte. Es wurden keine Derivat- oder Optionsgeschäfte gemeldet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider sold 6,750 shares, fell below 10% stake, ending reporting duties—signal skews slightly negative.

The sale represents only ~4.1% of Lazar’s post-split holdings, yet the structural implication is larger: he is no longer a statutory insider, limiting future disclosure. While the dollar amount is small, exiting the >10% bracket can suggest waning strategic interest or a planned liquidation path. The filing also cleans up an earlier conversion-count error, improving data integrity. Overall, impact is modest but directionally negative for sentiment, as insider selling and reduced transparency often weigh on micro-cap biotech names like Cyclacel.

CYCC � Riepilogo Transazione Insider (Modulo 4, presentato il 4/8/25)

  • Persona che segnala: David E. Lazar, precedentemente proprietario di almeno il 10%.
  • Transazione: Il 30/07/25 Lazar ha venduto 6.750 azioni ordinarie a $12,36 ciascuna, per un valore complessivo di circa $83.400.
  • Quota dopo la vendita: 155.838 azioni ordinarie detenute direttamente.
  • Effetto del frazionamento inverso: Le partecipazioni riflettono il frazionamento inverso 1-per-15 effettuato il 07/07/25.
  • Segnalazione di uscita: Dopo questa vendita, la quota di Lazar è scesa sotto la soglia del 10%, terminando lo status di insider ai sensi della Sezione 16.
  • Correzione di errore precedente: Una segnalazione del 28 febbraio aveva erroneamente indicato 354.738 azioni privilegiate Serie D già convertite in 162.588 azioni ordinarie (post-frazionamento).

Considerazioni per l'investitore: La cessione è modesta in termini assoluti ma rilevante perché elimina un ex grande azionista dagli obblighi di segnalazione insider, riducendo potenzialmente la trasparenza sulle sue future operazioni. Non sono state segnalate transazioni derivati o attività su opzioni.

CYCC � Resumen de Transacción de Insider (Formulario 4, presentado el 4/8/25)

  • Persona que reporta: David E. Lazar, anteriormente propietario de â‰�10%.
  • °Õ°ù²¹²Ô²õ²¹³¦³¦¾±Ã³²Ô: El 30/07/25 Lazar vendió 6,750 acciones ordinarias a $12.36 cada una, por un valor total aproximado de $83,400.
  • Participación tras la venta: 155,838 acciones ordinarias en propiedad directa.
  • Impacto del split inverso: Las participaciones reflejan el split inverso 1 por 15 realizado el 07/07/25.
  • Presentación de salida: Tras esta venta, la propiedad de Lazar bajó del umbral del 10%, finalizando su condición de insider bajo la Sección 16.
  • Corrección de error previo: Una presentación del 28 de febrero listó erróneamente 354,738 acciones preferentes Serie D que ya se habían convertido en 162,588 acciones ordinarias (post-split).

Conclusión para el inversor: La desinversión es modesta en términos absolutos pero significativa porque elimina a un antiguo gran accionista de las obligaciones de reporte como insider, lo que podría reducir la visibilidad futura de sus operaciones. No se reportaron transacciones con derivados ni actividad en opciones.

CYCC â€� ë‚´ë¶€ìž� 거래 요약 (ì–‘ì‹ 4, 25ë…� 8ì›� 4ì� 제출)

  • ë³´ê³ ìž�: David E. Lazar, ì´ì „ì—� 10% ì´ìƒ 보유ìž�.
  • 거래 ë‚´ìš©: 25ë…� 7ì›� 30ì�, Lazarê°€ 6,750ì£� 보통주를 주당 $12.36ì—� 매ë„하여 ì´� ì•� $83,400ì� 가치를 기ë¡í•�.
  • ë§¤ë„ í›� 보유 ì§€ë¶�: ì§ì ‘ 보유í•� 155,838ì£� 보통ì£�.
  • 역병í•� ì˜í–¥: 25ë…� 7ì›� 7ì� 시행ë� 1대 15 ì—­ë³‘í•©ì„ ë°˜ì˜í•� 보유 지분임.
  • 퇴출 ì‹ ê³ : ì´ë²ˆ 매ë„ë¡� Lazarì� 보유 ì§€ë¶„ì´ 10% 미만으로 떨어ì � 섹션 16 ë‚´ë¶€ìž� 지위가 종료ë�.
  • ì´ì „ 오류 수정: 2ì›� 28ì� 제출ë� ë³´ê³ ì„œì— ì´ë¯¸ 162,588ì£� 보통ì£�(병합 í›�)ë¡� 전환ë� 354,738ì£� 시리ì¦� D 우선주가 잘못 기재ë˜ì—ˆì�.

투ìžìž� 참고 사항: ë§¤ë„ ê·œëª¨ëŠ� 절대ì ìœ¼ë¡œëŠ” í¬ì§€ 않지ë§�, ì´ì „ 대주주가 ë‚´ë¶€ìž� ë³´ê³  ì˜ë¬´ì—서 제외ë˜ì–´ 향후 거래 íˆ¬ëª…ì„±ì´ ê°ì†Œí•� ìˆ� 있으므ë¡� 중요í•�. 파ìƒìƒí’ˆ 거래ë‚� 옵션 활ë™ì€ ë³´ê³ ë˜ì§€ 않ìŒ.

CYCC � Résumé de la Transaction d’Initié (Formulaire 4, déposé le 4/8/25)

  • Personne déclarant : David E. Lazar, auparavant détenteur d’au moins 10%.
  • Transaction : Le 30/07/25, Lazar a vendu 6 750 actions ordinaires à 12,36 $ chacune, pour une valeur totale d’environ 83 400 $.
  • Participation après la vente : 155 838 actions ordinaires détenues directement.
  • Impact du regroupement inversé : Les avoirs tiennent compte du regroupement inversé de 1 pour 15 effectué le 07/07/25.
  • Dépôt de sortie : Après cette vente, la participation de Lazar est passée en dessous du seuil de 10%, mettant fin à son statut d’initié selon la Section 16.
  • Correction d’une erreur antérieure : Un dépôt du 28 février avait listé par erreur 354 738 actions privilégiées Série D déjà converties en 162 588 actions ordinaires (post-regroupement).

À retenir pour l’investisseur : La cession est modeste en valeur absolue mais importante car elle retire un ancien grand actionnaire des obligations de déclaration d’initié, ce qui pourrait réduire la visibilité future de ses transactions. Aucune opération sur dérivés ni activité d’options n’a été signalée.

CYCC � Zusammenfassung der Insider-Transaktion (Formular 4, eingereicht am 4.8.25)

  • Meldende Person: David E. Lazar, zuvor Eigentümer von â‰�10%.
  • Transaktion: Am 30.07.25 verkaufte Lazar 6.750 Stammaktien zu je $12,36, mit einem Gesamtwert von ca. $83.400.
  • Anteil nach Verkauf: 155.838 direkt gehaltene Stammaktien.
  • Auswirkung des Reverse Splits: Die Bestände spiegeln den 1-zu-15 Reverse Split wider, der am 07.07.25 durchgeführt wurde.
  • Austrittsmeldung: Nach diesem Verkauf fiel Lazars Anteil unter die 10%-Schwelle, womit der Insider-Status nach Abschnitt 16 endet.
  • Vorheriger Fehler korrigiert: Eine Meldung vom 28. Februar listete fälschlicherweise 354.738 Series-D-Vorzugsaktien, die bereits in 162.588 Stammaktien (nach dem Split) umgewandelt wurden.

Investorenausblick: Die Veräußerung ist absolut gesehen eher gering, aber bedeutsam, da ein ehemaliger Großaktionär von den Insider-Meldepflichten entbunden wird, was die künftige Transparenz seiner Transaktionen verringern könnte. Es wurden keine Derivat- oder Optionsgeschäfte gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lazar David E.

(Last) (First) (Middle)
PH THE TOWERS, TOWER 200, 30B
WINSTON CHURCHILL, PAITILLA

(Street)
PANAMA CITY R1 07196

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cyclacel Pharmaceuticals, Inc. [ CYCC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/30/2025 S 6,750 D $12.36 155,838(1)(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split").
2. Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date.
Remarks:
This filing constitutes an exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Exchange Act as a result of the sale described above.
/s/ David E. Lazar 08/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Cyclacel Phar Pr

NASDAQ:CYCCP

CYCCP Rankings

CYCCP Latest News

CYCCP Latest SEC Filings

CYCCP Stock Data

8.54M
333.67k
1.18%
15.03%
Biotechnology
Pharmaceutical Preparations
Malaysia
BERKELEY HEIGHTS